300% Patient Growth: Learnings from MED’s Market Access Model
- Olivia Nguyen
- Dec 4
- 2 min read
A new blueprint for unlocking drug adoption in emerging markets
Pharma companies or Sponsor Clients entering Emerging Asia Pacific face the same persistent challenge: patients want treatment, hospitals want to provide it, but affordability blocks the pathway.
Yet despite the scale of the problem, market-access implementation has barely changed in decades. Programs remain:
Slow to localize
Fragmented across agencies
Dependent on manual assessment
High-risk in terms of compliance and patient data handling
Costly to scale
The result is a system that struggles to reach the very patients it is designed to help.
MED has rebuilt this system from the ground up.
A Market Access Platform Designed for Emerging Markets
The platform combines:
✔ Automated Enrollment & KYC
Digital onboarding where patients or family members can apply within minutes.
✔ AI-Driven Means Testing
Verified address, property value, neighborhood economics, and income modeling to classify patients into support tiers instantly.
✔ Out-of-pocket payment plan & Subsidy Management
From affordable payment plans to Discounts, everything is automated and compliant.
✔ Transparent Fund & Medicine Tracking
Hospitals, distributors, and Sponsor Clients receive end-to-end visibility — drastically reducing operational inefficiency.
This new infrastructure allows Sponsor Clients to roll out programs in 4–6 weeks, not months.
The Impact: A 300% Surge in Patient Enrollment
This model isn’t theoretical — it’s already delivering measurable outcomes.
Across Vietnam, the Philippines, and Indonesia, MED has driven:
3x growth in patient enrollment within 12 months
Access to 400+ hospitals
Remarkable 4.9/5 satisfaction across thousands of patients
Smoother hospital workflows and reduced administrative burden
Increased adherence and better lifetime treatment value
Faster geographic expansion for global sponsor clients
For high-value cancer drugs and rare disease treatments, improved affordability directly correlates with increased initiation and continuation. For lower-value chronic drugs, micro-financing unlocks thousands of new patients who could not previously afford therapy.
Why Sponsors Are Paying Attention
MED’s affordability structure does more than remove financial barriers — it creates a repeatable commercial model for emerging markets:
Predictable revenue
Lower operational costs
Faster time-to-market
Localization across multiple countries
High scalability for multi-drug portfolios
As global sponsors heightens its focus on emerging markets, platforms like MED set a new benchmark for what modern market access should look like: digital, automated, compliant, and truly patient-first.
Explore our Affordability Solutions now
